Efidac 24 Combination Cold/Allergy Medication Cleared by FDA
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Efidac 24 Combination Cold/Allergy Medication Cleared by FDA

PALO ALTO, Calif., April 3, 1996 -- ALZA Corporation (NYSE: AZA) today announced that Efidac 24(R) Pseudoephedrine/Brompheniramine, the first over-the-counter (OTC) 24-hour nasal decongestant/antihistamine combination product, has been cleared for marketing by the U.S. Food and Drug Administration.

Efidac 24(R) Pseudoephedrine/Brompheniramine utilizes ALZA's proprietary OROS(R) oral controlled-release technology to deliver the drugs pseudoephedrine hydrochloride and brompheniramine maleate for 24 hours, providing temporary relief of nasal congestion due to the common cold, hay fever, or other upper respiratory allergies associated with sinusitis, and temporary relief of runny nose, sneezing, itching of the nose or throat, and itchy, watery eyes due to hay fever or other upper respiratory allergies. Efidac 24(R) Pseudoephedrine/Brompheniramine was developed by ALZA on behalf of the former ALZA's OROS(R) Products Limited Partnership. Ciba Self-Medication, Inc. holds U.S. marketing rights to the product. Launch plans have not been disclosed.

Efidac 24(R) Pseudoephedrine/Brompheniramine is the third product to be cleared for marketing of a group of OROS(R) cold/allergy/sinus products based on ALZA's OROS(R) technology. Efidac 24(R) Pseudoephedrine, an OTC 24-hour nasal decongestant launched in 1993, was the first of these products to be cleared for marketing. Efidac 24(R) Chlorpheniramine, an OTC 24-hour antihistamine allergy medication, was introduced in the U.S. in the spring of 1995. Efidac 24(R) Pseudoephedrine and Efidac 24(R) Chlorpheniramine are manufactured by ALZA and marketed in the U.S. by Ciba Self-Medication under an agreement with ALZA .

ALZA Corporation, headquartered in Palo Alto, California, is a leader in the development and commercialization of innovative pharmaceutical products using advanced drug delivery technologies to add medical and economic value to drug therapies.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities